Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    MoneyHero

    MCap

    USD60m

    Last close

    USD2.35

    ▲ 0.55 (30.56%)

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Pharnext (PAR: ALPHA)

Last close As at 26/04/2024

EUR0.10

▲ 0.03 (42.86%)

Market capitalisation

1m

Advanced clinical-stage biopharmaceutical, Pharnext, is developing novel therapies for neurodegenerative diseases lacking curative and/or disease-modifying treatments. PXT3003 for Charcot-Marie-Tooth disease type 1A (CMT1A) is in advanced Phase III clinical trials with top-line data due in Q423.

Latest Insights

View More

Healthcare | Flash note

Pharnext — Potential licensing deals could add confidence

Healthcare | Update

Pharnext — Improving FY23 financial footing

Update

Pharnext — Revised legal structure to offer operational stability

Healthcare | Flash note

Pharnext — Neovacs trust to manage Pharnext deal
Visit Website

Sector

Healthcare

Key Management

  • Hugo Brugiere

    Chairman & CEO

Balance Sheet

Forecast net debt (€m)

42.6

Forecast gearing ratio (%)

79

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (87.2) (99) (99)
Relative (88) (99) (99)
52 week high/low €0.2/€0.0

Financials

Edison Investment Research is terminating coverage on ABC Arbitrage (ABCA), paragon (PGN), Foresight Solar Fund (FSFL), Kendrion (KENDR), Lithium Power International (LPI), Triple Point Energy Transition (TENT), 4iG (4IG), e-therapeutics (ETX), Pharnext (ALPHA) and Shield Therapeutics (STX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (fd) (c) P/E (x) P/CF (x)
2021A 3.6 (22.2) (30.6) (100.67) N/A N/A
2022A 2.3 (27.2) (38.5) (16.66) N/A N/A
2023E 1.9 (23.7) (24.7) (3579.47) N/A N/A
2024E 8.9 (10.8) (13.2) (1910.77) N/A N/A

Flash note

Healthcare

Pharnext — PREMIER trial completes patient recruitment

Update

Healthcare

Pharnext — Convertible debt terms revised

Update

Healthcare

Pharnext — Clinically healthy

Update

Healthcare

Pharnext — Back in the saddle again

Update

Healthcare

Pharnext — Pivotal Phase III initiated

Update

Healthcare

Pharnext — R&D day highlights

edison tv

Healthcare

Pharnext – executive interview

Initiation

Healthcare

Pharnext — New efficacy and new indications from old drugs